Payment overview · 2025
General Payments
$932.59
71 reported records · 15 companies
Healthcare provider profile · identity verified
Don E Heinkel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MUSCLE SHOALS, AL · NPI 1396738761
Verified facts
What the public records show
CMS Open Payments records show Don E Heinkel, M.D. received $932.59 in general payments during 2025 across 71 reported records.
Novo Nordisk Inc accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Ozempic, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $195.71 | 21.0% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $156.88 | 16.8% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $155.64 | 16.7% | 22 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $149.76 | 16.1% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $57.36 | 6.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $36.60 | 3.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.83 | 3.8% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.18 | 3.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.02 | 2.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.11 | 2.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.00 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.86 | 1.8% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $15.14 | 1.6% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.04 | 1.5% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $13.46 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $932.59 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $148.42 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $81.43 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $81.43 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $81.32 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $72.70 | 12 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $68.33 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $68.33 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $68.33 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $68.28 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.28 | 11 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $57.36 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.14 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.29 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $36.60 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $29.18 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $1.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 193 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
64 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
193 | 42 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
153 | 32 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1511 | 170 |
| Gabapentin | Gabapentin | 1042 | 156 |
| Alprazolam | Alprazolam | 761 | 90 |
| Tramadol Hcl | Tramadol Hcl | 669 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 544 | 163 |
| Potassium Chloride | Potassium Chloride | 527 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 470 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 448 | 126 |
| Omeprazole | Omeprazole | 403 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 355 | 106 |
| Lisinopril | Lisinopril | 354 | 103 |
| Pravastatin Sodium | Pravastatin Sodium | 330 | 90 |
| Metformin Hcl | Metformin Hcl | 301 | 81 |
| Trazodone Hcl | Trazodone Hcl | 280 | 78 |
| Losartan Potassium | Losartan Potassium | 272 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 259 | 65 |
| Furosemide | Furosemide | 235 | 75 |
| Diazepam | Diazepam | 202 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 199 | 25 |
| Ezetimibe | Ezetimibe | 198 | 55 |
| Buspirone Hcl | Buspirone Hcl | 195 | 53 |
| Famotidine | Famotidine | 195 | 53 |
| Farxiga | Dapagliflozin Propanediol | 193 | 42 |
| Sertraline Hcl | Sertraline Hcl | 178 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 177 | 126 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 175 | 57 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 175 | 53 |
| Baclofen | Baclofen | 168 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 38 |
| Clonazepam | Clonazepam | 160 | 21 |
| Eliquis | Apixaban | 153 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 36 |
| Pregabalin | Pregabalin | 150 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 53 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 141 | 35 |
| Montelukast Sodium | Montelukast Sodium | 138 | 44 |
| Carvedilol | Carvedilol | 131 | 34 |
| Celecoxib | Celecoxib | 127 | 39 |
| Meclizine Hcl | Meclizine Hcl | 127 | 51 |
| Methocarbamol | Methocarbamol | 127 | 39 |
| Jardiance | Empagliflozin | 119 | 23 |
| Naproxen | Naproxen | 113 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 107 | 34 |
| Meloxicam | Meloxicam | 106 | 31 |
| Allopurinol | Allopurinol | 101 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 23 |
| Fenofibrate | Fenofibrate | 99 | 24 |
| Mounjaro | Tirzepatide | 99 | 23 |
| Promethazine Hcl | Promethazine Hcl | 99 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 36 |
| Simvastatin | Simvastatin | 95 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 21 |
| Lorazepam | Lorazepam | 88 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 87 | 27 |
| Spironolactone | Spironolactone | 84 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 22 |
| Torsemide | Torsemide | 81 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 80 | 20 |
| Januvia | Sitagliptin Phosphate | 78 | 15 |
| Donepezil Hcl | Donepezil Hcl | 77 | 25 |
| Cefdinir | Cefdinir | 76 | 64 |
| Atenolol | Atenolol | 71 | 20 |
| Ozempic | Semaglutide | 71 | 15 |
| Bupropion Xl | Bupropion Hcl | 70 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 49 |
| Alendronate Sodium | Alendronate Sodium | 68 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 13 |
| Glimepiride | Glimepiride | 67 | 15 |
| Vascepa | Icosapent Ethyl | 66 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 13 |
| Prednisone | Prednisone | 65 | 35 |
| Ibuprofen | Ibuprofen | 64 | 21 |
| Linzess | Linaclotide | 64 | 20 |
| Metformin Hcl Er | Metformin Hcl | 64 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 29 |
| Memantine Hcl | Memantine Hcl | 62 | 26 |
| Myrbetriq | Mirabegron | 62 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 23 |
| Fluconazole | Fluconazole | 53 | 27 |
| Ondansetron Odt | Ondansetron | 52 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 13 |
| Rybelsus | Semaglutide | 49 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 11 |
| Irbesartan | Irbesartan | 43 | 12 |
| Trulicity | Dulaglutide | 42 | 12 |
| Verapamil Er | Verapamil Hcl | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Cilostazol | Cilostazol | 36 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | 14 |
| Benazepril Hcl | Benazepril Hcl | 34 | 11 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 33 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 33 | suppressed |
| Vraylar | Cariprazine Hcl | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 32 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | 12 |
| Nystatin | Nystatin | 26 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Fluocinonide | Fluocinonide | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Estradiol | Estradiol | 23 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Clotrimazole | Clotrimazole | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Fluocinonide-E | Fluocinonide/Emollient Base | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $932.59 · 71 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, AIRSUPRA, Ambulatory Monitoring & Diagnostics Undivided, BREZTRI, COMIRNATY, FARXIGA, GEMTESA, IBSRELA, JATENZO, Kerendia, Korlym, LINZESS, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Symbravo, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, WATCHMAN Access System, Wegovy, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error